Shares of Novo Nordisk surged 10% following positive early-stage results for its once weekly amycretin obesity drug, which led to a 22% weight reduction in obese and overweight patients compared to a 2.0% weight gain in the placebo group. The trial showed promising results for amycretin, a treatment that targets the same gut and pancreas hormones as Novo Nordisk’s flagship obesity drug Wegovy and diabetes treatment Ozempic. Novo Nordisk is also developing an amycretin obesity pill, with early-stage trials demonstrating a 13.1% weight loss after 12 weeks and mild-to-moderate side effects.
Full Article
Africa: ‘It Will Save Innocent American Lives’, Trump Signs New Law to Detain Immigrants
President Trump signed the Laken Riley Act into law, aimed at detaining undocumented immigrants involved in criminal activities, following bipartisan support in Congress. The law is named after a nursing student killed by an illegal immigrant and marks Trump's first legislative win of his second term. Trump praised Riley as a symbol of unity and credited the law for saving "countless innocent American lives." Full Article
Read more